BillionToOne, Inc. (BLLN) research
BillionToOne, Inc.- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Last price
- $116.07
- As of
BillionToOne, Inc. (BLLN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
As of . Source: SEC EDGAR filings for BLLN. Method and limitations.
Share the BLLN intelligence card
See BLLN live in the terminal
Track BLLN's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live BLLN terminal, freeActive signals for BLLN
- highCONSENSUS_BUY
5 tracked funds increased BLLN this 2026Q2, institutional consensus
- highCONSENSUS_BUY
4 tracked funds increased BLLN this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +7349% to BLLN (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +88% to BLLN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +15055% to BLLN (2026Q2)
FREE, NO ACCOUNT
Every signal on BLLN, as it fires
You are seeing 5 of 44 signals recorded on BLLN since 2026-05-29.
The five above landed across 2 days. The other 39 were recorded on 4 other days. 33 of the 44 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BLLN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 090168105 · 2026Q2 | $51M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 090168105 · 2026Q2 | $11.6M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 090168105 · 2026Q2 | $3.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 090168105 · 2026Q2 | $3.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 090168105 · 2026Q2 | $1.8M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BLLN
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
BLLN against its peers
BLLN's operating margin of 5.3% ranks in the 76th percentile of 18 Diagnostics & Research sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | BLLN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 305M USD | 77.2M USD | 68 | 19 |
| Gross margin | 68.3% | 62.2% | 73 | 12 |
| Operating margin | 5.3% | -17.6% | 76 | 18 |
| Net margin | 2.4% | -20.6% | 73 | 19 |
| Return on equity | 1.6% | -8.7% | 62 | 16 |
| P / E | 829.1x | n/a | n/a | 1 |
Peers (21): CDNA, QGEN, TWST, NEO, ICLR, PSNL, OPK, BDSX, BNR, IMDX, FONR, QUCY, MDXH, PRPO, IDXG, LDDD, AWHL, MBAI, NDRA, XWEL, ISPC. Left out: ANPCF (no annual filing), PMDI (period gap), ADVB (no annual filing), BIAF (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (BLLN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more BLLN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BLLNand get the insider, 13F, options, and confluence read in one view.